Alliance & IP

We are actively seeking partners for various alliances and collaborations. Please contact for more information.

Our current strong alliances are with leading pharmaceutical companies in China and the United States:

Jiangsu Hengrui Medicine
Simcere Pharmaceuticals
Jiangsu Chia-tai Tianqing Pharmaceutical
Shanghai Institute of Materia Medica
LSK BioPartners, Inc.
Ethical Oncology Science (EOS)
Bukwang Pharma

Our scientists use an integrated modern medicinal chemistry and computational chemistry to design and synthesize novel small molecules that lead to drug candidates. Our crucial capability is to, after analyzing databases of existing commercial drugs and clinical candidates, create innovative chemical fragments and scaffolds that may contribute better solubility, pharmacodynamics, pharcokinetics and toxicology profiles. Our quick lead optimizations are conducted on the bases of both regular in vitro and in vivo assays, which usually allows us to skip many insufficient in vitro murine assays in order to expedite the selection of the most promising preclinical candidates and clinical candidates.

Our patent filing is very active in order to protect our intellectual properties as well as our discoveries. The following is a list of our published or issued US patents and published PCT or EPO applications.

US 7129252, WO 05000232, EP 1633712
JP 10091683, KR 10-2005-7021014
US 7232825
US 7977346
US 7977346 (WO 2007084875)
US 8513283 (WO2008112408)
US 8148532 (WO2008112407)
US 8211911 (WO2010021918)